Ana Maria Arance

Sobre mi

Publicacions destacades

• Avelumab expanded access program in metastatic Merkel cell carcinoma: efficacy and safety findings from patients in Europe and the Middle East

  Autors:

  Ascierto, PA; Orlova, K; Grignani, G; Dudzisz-Sledz, M; Fenig, E;

  (...)

  Arance, A; Benincasa, E; Kostkova, L; Costa, N; Lorigan, P.

  Veure llistat complet d'autors

  Referència: International Journal Of Cancer 2021.

• Onset of fulminant type 1 diabetes mellitus following hypophysitis after discontinuation of combined immunotherapy

  Autors:

  Boswell, Laura; Casals, Gregori; Blanco, Jesus; Jimenez, Amanda; Aya, Francisco;

  de Hollanda, Ana; Halperin, Irene; Arance, Ana M; Mora, Mireia; Hanzu, Felicia A.

  Referència: Journal Of Diabetes Investigation 2021.

• Molecular Markers and Targets in Melanoma

  Autors:

  Teixido, C; Castillo, P; Alos, L; Arance, A; Martinez-Vila, C;

  Referència: Cells 2021.

• Delayed immune-related adverse events with anti-PD1-based immunotherapy in melanoma

  Autors:

  Owen, CN; Bai, X; Quah, T; Lo, SN; Allayous, C;

  (...)

  Lebbé, C; Carlino, MS; Sullivan, RJ; Long, GV; Menzies, AM.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2021.

• Quality of life in patients with BRAF-mutant melanoma receiving the combination encorafenib plus binimetinib: Results from a multicentre, open-label, randomised, phase III study (COLUMBUS)

  Autors:

  Gogas, H; Dummer, R; Ascierto, PA; Arance, A; Mandalà, M;

  (...)

  Suissa, J; Murris, J; Gollerkeri, A; Robert, C; Flaherty, KT.

  Veure llistat complet d'autors

  Referència: European Journal Of Cancer 2021.

• Initial stage of cutaneous primary melanoma plays a key role in the pattern and timing of disease recurrence

  Autors:

  Ertekin, Sumeyre Seda; Podlipnik, Sebastian; Riquelme-Mc Loughlin, Constanza; Barreiro-capurro, Alicia; Arance, Ana;

  Carrera, Cristina; Malvehy, Josep; Puig, Susana.

  Referència: Acta Dermato-Venereologica 2021.

• Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication

  Autors:

  Aya, F; Martínez, C; Arance, A; Gonzalez-Navarro, EA; Carcelero, E;

  Referència: Immunotherapy 2021.

• Long-term real-world experience with ipilimumab and non-ipilimumab therapies in advanced melanoma: the IMAGE study

  Autors:

  Dalle, S; Mortier, L; Corrie, P; Lotem, M; Board, R;

  (...)

  Scotto, J; Lord-Bessen, J; Moshyk, A; Kotapati, S; Middleton, MR.

  Veure llistat complet d'autors

  Referència: Bmc Cancer 2021.

• A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

  Autors:

  Atkinson, VG; Quaglino, P; Aglietta, M; Del Vecchio, M; Depenni, R;

  (...)

  Gogas, H; Banerjee, H; Saliba, T; de Jong, E; Neyns, B.

  Veure llistat complet d'autors

  Referència: Cancers 2021.

• Cobimetinib plus atezolizumab in BRAF^V600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study

  Autors:

  Gogas, H; Dréno, B; Larkin, J; Demidov, L; Stroyakovskiy, D;

  (...)

  Voulgari, A; Pitcher, B; Mulla, S; Flaherty, K; Arance, A.

  Veure llistat complet d'autors

  Referència: Annals Of Oncology 2021.